Fresenius Medical Care Holdings, Inc.

Len Usvyat

Peter Kotanko

Thomas C Blanchard

Franklin W Maddux

Nathan W Levin

Stephan Thijssen

Dugan W Maddux

Yuedong Wang

Caitlin Kelly Monaghan

Dinesh K Chatoth

Jeffrey Hymes

Ines A Dahne-Steuber

Kathleen Belmonte

Joanna L Willetts

Sheetal Chaudhuri

Melissa C Herman

Wendy Millette

Brian C Ellison

Judith E Moran

John Larkin

Teresa A Nash-Hampton

Joanna Willetts

Brian Ellison

Judith Moran

Exemplary systems and methods for estimating progression of chronic kidney disease in a patient and applying clinical interventions may include determining historic values of at least one patient parameter that varies as a function of the progression of the chronic kidney disease over time, and computationally estimating a trend corresponding to the historic values. Based on the trend, at least one marker may be automatically provided that identifies a clinical intervention and a time in the future when the clinical intervention is expected to be needed. Based on the at least one marker, clinical preparations may be executed at a time prior to the administration of the intervention in order to improve at least one of a) timeliness of the execution of the intervention and b) effectiveness of the intervention.

Systems and methods for treating and estimating progression of chronic kidney disease

Systems and methods for generating anonymized acoustic fingerprints. For a predetermined time interval, raw audio data associated with an environment can be captured and processed. Based on the captured raw audio data, a plurality of discrete data elements can be generated.

Systems and methods for generating anonymized acoustic fingerprints

A method for mitigating the spread of infectious diseases among dialysis patients is provided. The method comprises: receiving, by a prediction system and from a medical facility, individual treatment data indicating dialysis treatment information associated with a patient undergoing dialysis treatment; receiving, by the prediction system and from a blood testing laboratory, individual lab data indicating blood analysis information associated with the patient; determining, by the prediction system, disease analysis results for the patient based on inputting the individual treatment data and the individual lab data into a disease prediction machine learning (ML) model, wherein the disease analysis results indicate a likelihood of the patient being infected with a contagious disease; and providing, by the prediction system and to the medical facility, instructions indicating one or more responsive actions based on the disease analysis results.

System for assessing and mitigating potential spread of infectious disease among dialysis patients

A method and system for determining a patient's risk of developing an infection is disclosed. In one embodiment, the system and method includes extracting patient data from one or more databases corresponding to a pool of patients receiving treatment; using one or more predictive models with the extracted patient data to generate, for each of the patients in the pool of patients, a respective patient risk score for developing an infection within a selected time period; generating a report including at least a portion of the identified subset of the pool of patients and their respective patient risk scores; and transmitting the report to one or more health care facilities, the one or more health care facilities further identifying one or more patients from the portion of the identified subset of the pool of patients for interventional treatment, consultation, training, or combinations thereof.

Systems and methods for identifying risk of infection in dialysis patients

The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.

Method of identifying when a patient undergoing hemodialysis is at increased risk of death

The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, including systolic blood pressure, serum albumin concentration level, body weight, body temperature, serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.

Growing community of inventors

Boston, MA, United States of America

Len Usvyat